How We Evaluate Infant Formula

Start with the intended infant and exact product

We record market, format, package size, variant and label generation before comparing formulas. A US powder and a UK product with a similar name are separate identities. The FDA's marketed-formula list identifies products and intended populations; appearance there does not establish a particular lot's safety.

Keep the questions separate

We assess intended use, nutrient documentation, published ingredients, manufacturing controls, testing scope, regulatory history and certification correspondence. Affordability will be added after a separate audit. None of these dimensions becomes a single safety score.

An ingredient declaration shows what a cited label says. A laboratory report needs its own product, sample, method, analytes, units and limits. We do not transfer brand-level or market-wide evidence to a current can.

Research is reviewed before publication

The initial inventory contains 31 records and 25 complete published ingredient references. All 31 still need formulation verification; none has a physically verified can and a complete original lot-specific laboratory dossier.

Proposed Consider and Conditional assessments are editorial drafts. They do not mean proven safe. Approval requires a named reviewer, dated checklist and fresh recall/source checks. Held, recalled and archived records remain distinct. Pricing and affiliate availability cannot change an assessment.